Physician profile
Jason Amato
NPI 1609832476
$44,962.20
in general payments reported to CMS, 2019-2025
33 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $13K · 2021: $7,728 · 2022: $2,630 · 2023: $2,826 · 2024: $2,891 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,518 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,517.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,265.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $28,462.19 | 2019-2025 | Aklief, Oracea, Epsolay |
| Abbvie INC. | $2,421.26 | 2020-2025 | Botox, Skyrizi, Rinvoq |
| Amgen INC. | $2,077.45 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,714.29 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Allergan, INC. | $1,408.16 | 2019-2023 | |
| Dermavant Sciences, INC. | $1,278.08 | 2022-2024 | Vtama |
| Pfizer INC. | $1,234.74 | 2019-2025 | |
| Leo Pharma INC. | $781.30 | 2019-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $694.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $506.91 | 2021-2025 | |
| Almirall LLC | $498.62 | 2019-2025 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $493.92 | 2022-2025 | Sotyktu |
| Ucb, INC. | $482.06 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $480.58 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $434.90 | 2023-2025 | Tremfya |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $370.95 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $360.15 | 2019-2025 | Absorica Ld |
| Botanix Sb INC | $176.74 | 2025 | Sofdra |
| Organon LLC | $173.20 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $169.57 | 2023-2024 | Zoryve |
| Epi Health, LLC | $162.91 | 2019-2022 | |
| Genentech USA, INC. | $125.00 | 2021 | |
| Mission Pharmacal Company | $96.04 | 2019-2021 | |
| Incyte Corporation | $86.27 | 2022-2025 | Opzelura |
| Dermira, INC. | $65.46 | 2019-2021 | |
| Aclaris Therapeutics, INC. | $49.75 | 2019 | |
| Genzyme Corporation | $33.91 | 2019-2022 | |
| Astellas Pharma US INC | $33.38 | 2025 | Izervay |
| Sandoz INC. | $24.40 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $23.43 | 2019 | |
| Celgene Corporation | $20.41 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.43 | 2019 | |
| Prugen, INC. Pharmaceuticals | $6.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.